Insilico Medicine’s AI-Discovered Drug to Treat Lung Disease Enters Human Trial
PRESS RELEASE — Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055. ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine’s end-to-end AI-powered drug discovery platform. It is being developed …
Insilico Medicine’s AI-Discovered Drug to Treat Lung Disease Enters Human Trial Read More »
